• LAST PRICE
    6.8600
  • TODAY'S CHANGE (%)
    Trending Down-0.4000 (-5.5096%)
  • Bid / Lots
    6.8000/ 2
  • Ask / Lots
    7.1000/ 2
  • Open / Previous Close
    7.1000 / 7.2600
  • Day Range
    Low 6.8500
    High 7.1000
  • 52 Week Range
    Low 6.5000
    High 23.5000
  • Volume
    10,892
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.26
TimeVolumeGLTO
09:32 ET2047.1
10:18 ET4007.02
10:24 ET1007.02
12:51 ET6766.9701
01:33 ET9156.91
02:03 ET1007.005
02:38 ET27506.92
02:39 ET46826.86
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGLTO
Galecto Inc
9.1M
-0.4x
---
United StatesCUBT
Curative Biotechnology Inc
9.0M
-0.9x
---
United StatesMBIO
Mustang Bio Inc
9.2M
-0.1x
---
United StatesVRPX
Virpax Pharmaceuticals Inc
8.9M
-0.1x
---
United StatesVINC
Vincerx Pharma Inc
9.6M
-0.2x
---
United StatesCDT
Conduit Pharmaceuticals Inc
9.7M
-1.5x
---
As of 2024-11-08

Company Information

Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Contact Information

Headquarters
75 State Street, Suite 100BOSTON, MA, United States 02109
Phone
---
Fax
302-655-5049

Executives

Independent Chairman of the Board
Carl Goldfischer
President, Chief Executive Officer, Director
Hans Schambye
Chief Financial Officer
Jonathan Freve
Chief Operating Officer
Anders Pedersen
General Counsel, Corporate Secretary
Garrett Winslow

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.1M
Revenue (TTM)
$0.00
Shares Outstanding
1.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.27
EPS
$-19.33
Book Value
$29.81
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.